Clinical Trial: Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934447) titled 'Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE' on April 11.

Brief Summary: This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Study Start Date: April 08

Study Type: INTERVENTIONAL

Condition: CAR T Cell Therapy Systemic Lupus Erythematosus BCMA

Intervention: BIOLOGICAL: anti-BCMA/CD70-CAR-T cells

Three dose groups (0.3x105/kg, 1x105/kg, 3x105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Recruitment Status: RECRUITING

Sponsor: The Children's Ho...